cas 144-55-8, Sodium bicarbonate | Articles data

Articles about 144-55-8Total 126 be found

Article title
Article abstract
Author
Journal number and time
Download

Anion inhibition profiles of the γ-carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei responsible of melioidosis and highly drug resistant to common antibiotics
Burkholderia pseudomallei is a Gram-negative saprophytic bacterium responsible of melioidosis, an endemic disease of tropical and sub-tropical regions of the world. A recombinant γ-CA (BpsγCA) identified in the genome of this bacterium was cloned and puri
Del Prete, Sonia,Vullo, Daniela,Di Fonzo, Pietro,Osman, Sameh M.,AlOthman, Zeid,Supuran, Claudiu T.,Capasso, Clemente
p. 575 - 580
(2017)
Read Online

-
-
Oglesby, N. E.
p. 2352 - 2362
(1929)
Read Online

The Alkali Metal Salts of Methyl Xanthic Acid
Methyl xanthates of the type M(SSC-OMe) (M = Li–Cs) are readily formed when carbon disulfide is reacted with the corresponding alkali metal hydroxides in methanol exposed to air, or with the alkali metal methoxides in dry methanol or THF under exclusion of air. The reactions are easily monitored by 13C NMR spectroscopy. The Na, K, Rb, and Cs salt could be isolated in high yields, while the Li salt decomposed upon attempted isolation. All compounds are readily complexed by crown ethers and form isolable 1:1 adducts, including the elusive Li salt. All products were studied by NMR (1H, 13C, and alkali metal nuclei) and IR spectroscopy, and most of them where structurally characterized by single-crystal X-ray diffraction. Li(SSC-OMe)(12c4) (12c4 = [12]crown-4) and Cs(SSC-OMe)(18c6) (18c6 = [18]crown-6) represent the first structurally characterized lithium and caesium xanthate complexes, respectively.
Liebing, Phil,Schmeide, Marten,Kühling, Marcel,Witzorke, Juliane
p. 2428 - 2434
(2020)
Read Online

CO2 capture and release of Na0.7MnO2.05 under water vapor at 25–150?°C
Sodium manganates with a layered structure, Na0.7MnO2.05, have been applied to a novel material for CCUS (CO2 capture, utilization, and storage), capable of capturing CO2 at 25 °C in the presence of water vapor and releasing CO2 at 150 °C. The temperatures of capturing and releasing CO2 of Na0.7MnO2.05 were remarkably lower than those of other traditional metal oxides. The CO2 absorption and desorption properties of Na0.7MnO2.05 were investigated by various methods, such as thermogravimetry, Fourier transform infrared spectroscopy, X-ray diffractometry, and gas chromatography. These investigations confirmed that Na0.7MnO2.05 absorbed CO2 at 25 °C in the presence of water vapor to produce NaHCO3 and a birnessite and the CO2 absorption was promoted by increasing relative humidity and CO2 concentration. The CO2 absorption at 25 °C of Na0.7MnO2.05 was promoted by the formation of a strong basic solution on Na0.7MnO2.05, caused by the elution of Na ions from the interlayer of Na0.7MnO2.05 into water, adsorbed on the Na0.7MnO2.05 surface. Furthermore, Na0.7MnO2.05 was regenerated by heating the CO2-absorbed Na0.7MnO2.05 at temperatures as low as 150 °C. The low-temperature regeneration indicates that Na0.7MnO2.05 can be a low-energy consumption material for capturing and releasing CO2 at low temperatures.
Yanase, Ikuo,Takano, Takuya
p. 212 - 218
(2019)
Read Online

β-Na2TeO4: Phase Transition from an Orthorhombic to a Monoclinic Form. Reversible CO2 Capture
The present work concerns the tellurate Na2TeO4 which has a 1D structure and could then present a CO2 capture ability. It has been synthesized in a powder form via a solid-state reaction and structurally characterized by thermal X-ray diffraction experiments, Raman spectroscopy, and differential scanning calorimetry. The room temperature structure corresponds to the β-Na2TeO4 orthorhombic form, and we show that it undergoes a reversible structural transition near 420 °C toward a monoclinic system. Ab initio computations were also performed on the room temperature structure, the Raman vibration modes calculated, and a normal mode attribution proposed. In agreement with our expectations, this sodium oxide is able to trap CO2 by a two-step mechanism: Na+/H+ exchange and carbonation of the released sodium as NaHCO3. This capture is reversible since CO2 can be released upon heating by recombination of the mother phase.
Galven, Cyrille,Pagnier, Thierry,Rosman, No?l,Le Berre, Fran?oise,Crosnier-Lopez, Marie-Pierre
p. 7334 - 7345
(2018)
Read Online

Investigation of the Formation of Wegscheiderite, Na2CO3*3NaHCO3
The reaction of sodium carbonate with water vapour and carbon dioxide has been studied in the temperature range 343-368 K in pure carbon dioxide, and at pressures of water vapour between 1 * 104 and 5 * 104 N m-2.The produ
Ball, Matthew C.,Clarke, Rosemary A.,Strachan, Alec N.
p. 3683 - 3686
(1991)
Read Online

Photochemical Formic Acid Dehydrogenation by Iridium Complexes: Understanding Mechanism and Overcoming Deactivation
The mechanism of photochemical formic acid dehydrogenation catalyzed by [CpIr(bpy)(Cl)]+ (1, bpy = 2,2′-bipyridine) and [Cp Ir(bpy-OMe)(Cl)]+ (1-OMe, bpy-OMe = 4,4′-dimethoxy-2,2′-bipyridine) is examined. The catalysts operate with good turnover frequency (TOF) across an unusually wide pH range. Above pH 7, the evolved gas is >95% pure H2 (along with traces of CO2 but no detectable CO). Light-triggered H2 release from a metal hydride intermediate is found to be the turnover-limiting step, based on the observed first-order dependence on catalyst concentration, saturation behavior in formate concentration, and direct in situ observation of a metal hydride resting state during turnover. Deactivation pathways are identified, including ligand loss and aggregate formation, precipitation of insoluble forms of the catalyst, and deprotonation of the iridium hydride intermediate. Guided by mechanistic insights, improved catalytic activity (initial TOF exceeding 50 h-1), stability (>500 turnovers at nearly 5 atm), and selectivity (>95% H2 gas) are achieved.
Barrett, Seth M.,Slattery, Samuel A.,Miller, Alexander J. M.
p. 6320 - 6327
(2015)
Read Online

Carbon dioxide conversion into the reaction intermediate sodium formate for the synthesis of formic acid
Increased carbon dioxide (CO2) emissions from anthropogenic activities are a contributing factor to the growing global warming worldwide. The economical method to recover and effectively reuse CO2 is through adsorption and absorption. In this study, CO2 is absorbed into the solution of sodium hydroxide having various concentrations (0.01, 0.1, 0.5, 1.0, 3.0 and 5.0?N), and the impact of the solution pH on the various product formation was observed. The resultant products formed at different pH of the absorbing solution are sodium carbonate at pH 10, Trona at pH 9, and sodium hydrogen carbonate at pH 8. The products formed are confirmed through X-ray diffraction analysis. After pH optimization, the sodium hydrogen carbonate formed at pH 8 is converted into sodium formate through hydrogenation in the presence of nickel ferrite catalyst at 80 °C and atmospheric pressure. The sodium formate produced is then used as a precursor to synthesize formic acid upon simple reaction with sulfuric acid. A reaction % age yield of 79 ± 0.2% formic acid is noted. Condensed formic acid vapors are later analyzed, using a high performance?liquid chromatography for the qualitative analysis.
Masood, Muhammad Hanan,Haleem, Noor,Shakeel, Iqra,Jamal, Yousuf
p. 5165 - 5180
(2020/09/03)

CATALYTIC CONVERSION OF CARBON DIOXIDE TO METHANOL
The present disclosure relates to a new catalytic process for the production of methanol from carbon dioxide, comprising: (1) the conversion of carbon dioxide and hydrogen to formic acid or formate salts; (2) converting the formic acid or formate salts to diformate esters of diols; (3) hydrogenating the diformate esters to methanol and diols. The diols produced from the hydrogenation reaction can be recovered and re-used to prepare the diformate esters.
-
Page/Page column 25; 26

(2019/10/29)

Macrocyclic MCL-1 inhibitors and methods of use
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
Paragraph 1023

(2019/02/28)

CATALYST FOR DEHYDROGENATION REACTION OF FORMATE AND HYDROGENATION REACTION OF BICARBONATE AND PREPARATION METHOD THEREOF
Provided is a method for preparing a catalyst for a dehydrogenation reaction of formate and a hydrogenation reaction of bicarbonate, the method including: adding a silica colloid to a polymerization step of polymerizing aniline and reacting the resulting mixture to form a poly(silica-aniline) composite; carbonizing the corresponding poly(silica-aniline) composite under an atmosphere of an inert gas; removing silica particles from the corresponding poly(silica-aniline) composite to form a polyaniline-based porous carbon support; and fixing palladium particles on the corresponding polyaniline-based porous carbon support to prepare the catalyst.
-
Page/Page column 6

(2018/04/20)

A Carbon-Neutral CO2 Capture, Conversion, and Utilization Cycle with Low-Temperature Regeneration of Sodium Hydroxide
A highly efficient recyclable system for capture and subsequent conversion of CO2 to formate salts is reported that utilizes aqueous inorganic hydroxide solutions for CO2 capture along with homogeneous pincer catalysts for hydrogenation. The produced aqueous solutions of formate salts are directly utilized, without any purification, in a direct formate fuel cell to produce electricity and regenerate the hydroxide base, achieving an overall carbon-neutral cycle. The catalysts and organic solvent are recycled by employing a biphasic solvent system (2-MTHF/H2O) with no significant decrease in turnover frequency (TOF) over five cycles. Among different hydroxides, NaOH and KOH performed best in tandem CO2 capture and conversion due to their rapid rate of capture, high formate conversion yield, and high catalytic TOF to their corresponding formate salts. Among various catalysts, Ru- and Fe-based PNP complexes were the most active for hydrogenation. The extremely low vapor pressure, nontoxic nature, easy regenerability, and high reactivity of NaOH/KOH toward CO2 make them ideal for scrubbing CO2 even from low-concentration sources - such as ambient air - and converting it to value-added products.
Kar, Sayan,Goeppert, Alain,Galvan, Vicente,Chowdhury, Ryan,Olah, Justin,Prakash, G. K. Surya
supporting information
p. 16873 - 16876
(2018/11/06)

Carbon dioxide as a pH-switch anti-solvent for biomass fractionation and pre-treatment with aqueous hydroxide solutions
Rice husks (or rice hulls) pre-treated with aqueous potassium hydroxide solutions showed excellent glucose yields during enzymatic saccharification. CO2 addition to the hydroxide solutions precipitated the dissolved rice husk silica as a nanoporous powder, while Ca(OH)2 addition regenerated the hydroxide solution and precipitated the dissolved lignin. Fractionation of the biomass was thus achieved using CO2 addition as a reversible pH-switch, and the hydroxide could be repeatedly recycled while maintaining biomass pre-treatment and fractionation efficacy.
To, Trang Quynh,Kenny, Ceire,Cheong, Soshan,Aldous, Leigh
supporting information
p. 2129 - 2134
(2017/07/18)

Liquid crystal compound having tetrafluoropropenyl, liquid crystal composition, and liquid crystal display element
A liquid crystal compound having high stability to heat and light, etc., a high clearing point, a low minimum temperature of liquid crystal phase, a low viscosity, a suitable optical anisotropy, a large dielectric anisotropy, a suitable elastic constant, and good compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound, and a LCD element using the composition are described. The compound is represented by formula (1): wherein, for example, R1 is C1-10 alkyl, ring A1, ring A2, ring A3, ring A4 and ring B1 are independently 1,4-cyclohexylene, 1,4-phenylene, 1,4-phenylene in which at least one hydrogen is substituted with halogen, 1,3-dioxane-2,5-diyl, or tetrahydropyran-2,5-diyl, Z1, Z2, Z3 and Z4 are single bonds, l, m, n and o are independently 0 or 1, and l+m+n+o≧1.
-
(2016/06/13)

Method for preparing taurine and co-producing bicarbonate
The invention discloses a method for preparing taurine and co-producing bicarbonate. The method comprises the step of leading carbon dioxide gas or adding a carbon dioxide water solution to an amino ethyl sulfonate water solution of alkali metal or ammonium to regulate a pH value so as to obtain the taurine and the bicarbonate. The method can replace an existing taurine preparation method of using sulfuric acid or sulfur dioxide to regulate the pH value, meanwhile can treat boiler exhaust gas, turns the carbon dioxide in the exhaust gas into wealth, co-produces the bicarbonate and is a safe, environmentally-friendly and energy-saving method for producing the taurine and co-producing the bicarbonate.
-
Paragraph 0045; 0046; 0047; 0048

(2016/10/08)

METHODS AND CATALYST SYSTEMS FOR CARBON DIOXIDE CONVERSION
Disclosed herein are embodiments of a heterogeneous catalyst system and methods of using the same to convert CO2-derived compounds to formate, formic acid, or a mixture thereof. The disclosed heterogeneous catalyst systems exhibit superior reactivity and stability in comparison to homogeneous catalyst systems and also can convert a variety of CO2-derived compounds to formate, formic acid, or mixtures thereof, in high yields using economical and environmentally friendly reaction conditions.
-
Paragraph 123

(2016/06/06)

Effect of 2-propanol on the transfer hydrogenation of aldehydes by aqueous sodium formate using a rhodium(i)-sulfonated triphenylphosphine catalyst
In water/2-propanol mixtures [RhCl(mtppms)3] (mtppms = monosulfonated triphenylphosphine) was an efficient catalyst for the selective C=C reduction of trans-3-phenyl-2-propenal (trans-cinnamaldehyde) by hydrogen transfer from formate at temperatures as low as 30 °C. An outstandingly high catalyst turnover frequency of 1214 h-1 was determined at 70 °C. A possible mechanism of the reaction is suggested on the basis of kinetic studies and 1H- and 31P-NMR spectroscopic identification of the major Rh(i) species in the reaction mixtures as cis-mer-[H2RhX(mtppms)3] (X = HCOO- or H2O). It was established that a large part but not all of the rate increase observed in water/2-propanol mixtures in comparison with systems with neat water as solvent was the consequence of complete dissolution of trans-cinnamaldehyde on the effect of the co-solvent. Nevertheless, the rate showed a significant further increase with increasing 2-propanol concentration even in homogeneous solution and this was ascribed to changes in the solvent structure. The high catalyst activity in this solvent mixture allowed the transfer hydrogenation of citral. Although good to excellent conversions were observed at 30-70 °C, a useful degree of selectivity in hydrogenation of C=C vs. C=O bonds could not be achieved.
Kathó, ágnes,Szatmári, Imre,Papp, Gábor,Joó, Ferenc
p. 339 - 344
(2015/11/24)

Carbazole compounds and therapeutic uses of the compounds
Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
-
(2015/09/28)

PAR4 AGONIST PEPTIDES
The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.
-
Page/Page column

(2013/11/06)

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.
-
(2012/08/08)

METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
-
(2012/12/13)

TLE3 AS A MARKER FOR CHEMOTHERAPY
Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
-
(2011/02/18)

Method for Generating a Recombinant Clonal Cell Line and Novel Reagents for Use in the Method
A method for generating a recombinant clonal cell line expressing a target cell surface receptor at a specific level of expression from a cell population comprising cells transfected with a plasmid encoding the cDNA sequence of the target receptor and expressing the target cell surface receptor, the method comprising (c) incubating the cell population with a receptor specific fluorescent ligand (d) selecting single cells from step (c) expressing the target cell surface receptor by monitoring the specific binding of the fluorescent ligand using flow cytometry; and novel fluorescent ligands.
-
Page/Page column

(2013/03/26)

PHOSPHORESCENT EMITTERS AND HOST MATERIALS WITH IMPROVED STABILITY
Devices containing a particular combination of organic compounds are provided. In particular, the devices contain twisted aryl compounds having extended conjugation (i.e., the twisted aryl is substituted with an additional aryl group) in combination with dibenzothiophene or dibenzofuran containing host materials. The organic light emitting devices may provide improved stability color, lifetime and manufacturing. Compounds containing a twisted aryl having extended conjugation are also provided.
-
(2011/04/18)

TEMPLATES FOR NUCLEATION AND PROPAGATION OF PEPTIDE SECONDARY STRUCTURE
Compounds having the Formula I and pharmaceutically acceptable salts thereof are provided in which the variables are described herein. Methods of making the compounds of Formula I are also disclosed.
-
(2010/09/17)

DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES
Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.
-
(2009/04/24)

Therapeutic quinazoline derivatives
A compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O), S(O)2 or NR6 where R6 is hydrogen of C1-6alkyl; R5 is an optionally substituted 6-membered aromatic ring containing at least one nitrogen atom, and R1, R2, R3, R4 are independently selected from halogeno, cyano, nitro, C1-3alkylsulphanyl, —N(OH)R7— (wherein R7 is hydrogen, or C1-3alkyl), or R9X1— (wherein X1 represents a direct bond, —O—, —CH2—, —OC(O), —C(O)—, —S—, —SO—, —SO2—, —NR10C(O)—, —C(O)NR11—, —SO2NR12—, —NR13SO2— or NR14— (wherein R10, R11, R12, R13 and R14 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl), and R9 is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy; provided that at least one of R2 or R3 is other than hydrogen. These compounds inhibit aurora 2 kinase and are useful in the preparation of medicaments for the treatment of proliferative disease such as cancer.
-
(2008/06/13)

Reagents and methods for use in cancer diagnosis, classification and therapy
Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
-
(2008/06/13)

THROMBIN DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME
The present invention provides a thrombin derivative, comprising an A chain and a B chain, the B chain having an amino acid sequence in which one or more kinds of active center amino acids selected from the group consisting of serine at position 205, glycine at position 203, aspartic acid at position 99, and histidine at position 43 in an amino acid sequence of a thrombin B chain are substituted, having the properties: (1) cleaving a thrombin substrate at the ratio of 10% or less when it is reacted with the thrombin substrate in 50 mM Tris-HCl (pH 7.4) containing 0.1 M NaCl at 37°C for 3 hours, and (2) maintaining a structure of exosite I.
-
(2008/06/13)

METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
-
(2008/06/13)

Conjugated complement cascade inhibitors
The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.
-
(2008/06/13)

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
-
(2008/06/13)

Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.
-
(2008/06/13)

Trioxane derivatives
This invention relates to compounds containing a trioxane moiety, especially certain artemisinin derivatives, which have cytotoxic and antitumour activity and their use in the treatment of cancer. Some of these compounds comprise a ligand which is capable of binding to a nucleic acid and a group containing a trioxane moiety which is capable of acting as source of free radicals which are capable of chemically interacting with a nucleic acid. Processes for the preparation of such compounds and pharmaceutical compositions containing such compounds are also provided.
-
(2008/06/13)

1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
Novel amines of formulas (1), (1C), (1F), (1G) and (1H) or a pharmaceutical acceptable salt thereof wherein n is an integer of from 0 to 2; m is an integer of from 0 to 3; R is sulfonamide, amide, phosphonic acid, heterocycle, sulfonic acid, or hydroxamic acid; A′ is a bridged ring selected from (1), (2), (3), (4), (5) wherein is the point of attachment; Z1to Z4are each independently selected from hydrogen and methyl; o is an integer of from 1 to 4; and p is an integer of from 0 to 2. In formula (1) above R cannot be sulfonic acid when m is 2 and n is 1 are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, especially irritable bowel syndrome.
-
(2008/06/13)

VLA-4 inhibitor compounds
Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.
-
(2008/06/13)

Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
The present invention relates to a compound with aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amindonoaryl-alanines, represented by formula (1), a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate or an isomer thereof, which are inhibitors of coagulation enzyme, factor Xa (FXa). The present invention also relates to a pharmaceutical composition containing the compound, and a method of using the same as an anticoagulant agent for treatment and prevention of thrombosis disorders.
-
(2008/06/13)

Antithrombotic compound
The present invention relates to compounds of the formula (I), wherein R is independently SO3? or CH3; the spacer is a flexible spacer of a length of 13-25 atoms the charge of the pentasaccharide residue is compensated by positively charged counterions; and the total number of sulfate groups in the pentasaccharide residue is 4, 5 or 6; or a pharmaceutically acceptable salt, a prodrug or a solvate thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombin-related diseases.
-
(2008/06/13)

Process for producing nucleic acid derivative
A process for efficiently producing a nucleic acid derivative by condensing a specific nitrogen-containing heterocyclic compound such as a dinitrogen 6-membered heterocyclic compound or a trinitrogen 5-membered heterocyclic compound with a pentose using a less expensive and safe reagent. Namely, a process for producing a nucleic acid derivative by condensing a dinitrogen 6-membered heterocyclic compound or a trinitrogen 5-membered heterocyclic compound with a pentose in the presence of an iron halide.
-
(2008/06/13)

Neurokinin antagonists for use as medicaments
A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
-
(2008/06/13)

Polycyclic guanine derivative phosphodiesterase V inhibitors
A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases:
-
(2008/06/13)

Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
The invention relates to the use of compounds having combined sopamine D2 agonistic activity, 5-HT1A agonistic activity and a adrenoceptor agonistic activity for the treatment of CNS disorders such as Parkinson's disease.
-
(2008/06/13)

Novel non-imidazole compounds
Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
-
(2008/06/13)

Piperazine and piperidine compounds
The invention relates to a group of novel piperazine and piperidine derivatives of the formula wherein Y is hydrogen, halogen, alkyl (1-3C), or CN, CF3, OCF3, SCF3, alkoxy(1-3C), amino or mono- or dialkyl(1-3C) substituted amino or hydroxy, X is O, S, SO or SO2, -Z represents —C, =C or —N, R1 and R2 independently represent hydrogen or alkyl (1-3C), Q is benzyl or 2-, 3- or 4-pyridylmethyl, wich groups may be substited with one or more more substituents from the group halogen, nitro, cyano, amino, mono- or di (1-3C)alkylamino, (1-3C) alkoxy, CF3, OCF3, SCF3, (1-4C)-alkyl, (1-3C)alkylsulfonyl or hydroxy,and salts and prodrugs thereof. It has been found that these compounds have interesting pharmacological properties due to a combination of (partial) agonism towards the members of the dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors.
-
(2008/06/13)

Basal cell markers in breast cancer and uses thereof
The invention provides a variety of reagents for use in the diagnosis and management of breast cancer. The invention utilizes cDNA microarray technology to identify genes whose expression profile across a large group of tumor samples correlates with that of cytokeratin 5 and cytokeratin 17, markers for basal cells of the normal mammary lactation gland. The invention demonstrates that tumors that express cytokeratin 5/6 and/or 17 have a poor prognosis relative to tumors overall. The invention provides basal marker genes and their expression products and uses of these genes for diagnosis of breast cancer and for identification of therapies for breast cancer. In particular, the invention provides basal marker genes including cadherin3, matrix metalloproteinase 14, and cadherin EGF LAG seven-pass G-type receptor 2. The invention provides antibodies to the polypeptides expressed by these genes and methods of use thereof.
-
(2008/06/13)

6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both
The invention provides compounds with antagonism against excitatory amino acid receptors, in particular, AMPA receptor having 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof as effective ingredients, and processes for the preparation of both. These compounds relate to 6-substituted heteroquinolinecarboxylic acid derivatives represented by a general formula (1) (wherein A denotes a single bond or methylene (CH2), Y denotes a nitrogen atom or ═CH—, V denotes a single bond or methylene (CH2), T denotes a hydroxyl group, amino group, lower alkoxycarbonyl group, carboxyl group, aldehyde group or the like, R denotes a nitro group, trifluoromethyl group or halogen atom, and R1denotes a hydroxyl group or lower alkoxy group), and addition salts thereof.
-
(2008/06/13)

NITROGENOUS FIVE-MEMBERED RING COMPOUNDS
The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I] : wherein symbols in the formula have the following meanings;A: -CH2- or -S-,B: CH or N,R1: H, a lower alkyl group, etc.,X: a single bonding arm, -CO-, -Alk-CO-, -COCH2-, -Alk-O-, -O-CH2-, -SO2-, -S-, -COO-, -CON(R3)-, -Alk-CON(R3)-, -CON(R3)CH2-, -NHCH2-, etc.,R3: hydrogen atom or a lower alkyl group,Alk: a lower alkylene group, andR2: (1) a cyclic group which may be substituted, (2) a substituted amino group, etc., provided that when X is -CO-, then B is N, or a pharmaceutically acceptable salt thereof.
-
(2008/06/13)

Substituted tetraarylethylene compounds
The present invention seeks to provide novel tetraarylethylene compounds which are substituted on the aryl rings ortho to the ethylenic carbon atoms and processes for the preparation for such compounds. The compounds have potential use as molecular templates.
-
(2008/06/13)

Synthesis of compounds and libraries of compounds
The present invention provides a system for the production of chemical compounds and libraries of compounds that are complex, stereochemically and regioselectively pure, and may mimic the structural or functional properties of a peptide. The invention provides methods for producing collections of peptidomimetic compounds which, in one preferred embodiment, comprises (1) providing two diversifiable monomers containing terminal reactive moieties; (2) reacting the monomers under conditions that allow for the control of stereochemistry as well as chemoselectivity; and (3) generating diversifiable isolable compounds or libraries of compounds. In another preferred embodiment, a collection of peptidomimetic compounds is provided by (1) providing at least one diversifiable monomer containing terminal reactive moieties; (2) reacting the monomer with a reagent under conditions that allow for the control of stereochemistry as well as chemoselectivity; and (3) generating diversifiable isolable compounds or libraries of compounds. In another broader aspect, the present invention provides for the synthesis of a collection of compounds comprising peptidomimetics and non-peptidomimetics alike having stereodiversity. This method involves the steps of (1) selecting desired synthetic precursors having a predefined stereochemical relationship; (2) reacting the synthetic precursors so that a compound having a specific stereochemistry is obtained; and (3) repeating these steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained. In certain preferred embodiments, a library of compounds having only diversity of stereochemistry is provided. In certain other preferred embodiments, a library of compounds having structural diversity and stereochemical diversity is provided. The present invention also provides various chemical compounds useful in the inventive methods for production of complex peptidomimetic libraries. The peptidomimetic and stereodiverse compounds of the inventive method are useful for interactions with receptors in cells and may emulate the structure and functionality of peptides.
-
(2008/06/13)

QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3) - AND NEUROKININ 2 (NK-3) RECEPTOR ANTAGONISTS
A compound of formula (I): or a salt thereof, or a solvate thereof, wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkylaminoalkyl, di C1-6 alkylaminoalkyl, C1-6 acylaminoalkyl, C1-6 alkoxyalkyl, C1-6 alkylcarbonyl, carboxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonyl C1-6 alkyl, aminocarbonyl, C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, halogeno C1-6 alkyl; or R is a group--(CH2)p--wherein p is 2 or 3 which group forms a ring with a carbon atom of Ar; R1 represents hydrogen or up to four optional subtitutents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino or mono-and di-C1-6 alkylamino; R2 represents hydrogen, C 1-6-alkyl, hydroxy, halogen, cyano, amino, mono-or di-C1-6-alkylamino, alkylsulphonylamino, mono-or di-C1-6-alkanoylamino wherein any alkyl group is optionally substituted with an amino group or with a mono-or di-alkylamino group, or R2 is a moiety--X--(CH2)n--Y wherein X is a bond or--O--and n is an integer in the range of from 1 to 5 providing that when X is--O--n is only an integer from 2 to 5 and Y represents a group NY1Y2 wherein Y1 and Y2 are independently selected from hydrogen, C1-6-alkyl, C1-6-alkenyl, aryl or aryl-C1-6-alkyl or Y is hydroxy, halogen or an optionally substituted N-linked single or fused ring, heterocyclic group, R3 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R4 represents hydrogen or C1-6 alkyl; a process for the preparation of such a compound, a pharmaceutical compositon containing such a compound and the use of such a compound or composition in medicine.
-
(2008/06/13)

Tripeptidylpeptidase inhibitors
A compound of formula wherein the substituents are defined as in the specification and salts or hydrates thereof is disclosed as well as a method of treating disorders associated with the inactivation or excessive degradation of cholecystokinin.
-
(2008/06/13)

Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds
Arginine mimetic peptides according to Formula I of this application have a stimulating effect on bone formation and are useful for the treatment of bone metabolic disorders.
-
(2008/06/13)